 RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2021 GLOBE NEWSWIRE -- BioCryst Pharmaceuticals, Inc. Nasdaq: BCRX today announced that the company will present four abstracts, including one Distinguished Industry Oral Abstract, on oral, once-daily ORLADEYO berotralstat for the prophylactic treatment of hereditary angioedema HAE at the Annual Scientific Meeting of the American College of Allergy, Asthma Immunology ACAAI. The meeting will take place in New Orleans, Louisiana, and online, from November 4-8, 2021. 